Everything tagged "growth" across the TickerSpark archives.
Accenture posted solid Q3 growth, strong free cash flow, and early AI traction, but its investment case still depends on execution through a heavy acquisition cycle.
LuxExperience is showing real margin progress at Mytheresa and across its luxury portfolio, but the group still carries thin profitability and negative cash flow. The stock looks like a Hold as management works toward its ambitious medium-term targets.
AppLovin is delivering rapid revenue and earnings growth as its AI-driven Axon platform scales, but the stock already prices in a lot of execution. The report still supports a Buy rating, with model timing and valuation the key watchpoints.
Vertex is executing well across cystic fibrosis, with ALYFTREK, CASGEVY, and JOURNAVX all contributing to growth while the renal pipeline and Crinetics deal broaden the story. The stock earns a Buy on durable cash generation and a fair value estimate of $560.
Palo Alto Networks is delivering strong revenue, ARR, and platform expansion, but the stock already prices in a lot of that momentum. The report lands on a Hold as valuation leaves limited upside unless execution stays exceptional.
Lam Research posted record fiscal 2026 results as AI-related packaging, memory, and customer support revenue broadened the growth story. Valuation remains the main constraint, but execution and spending momentum support a Buy view.
Madison Air Solutions is executing well, with Q2 revenue up 21% and backlog surging 133%, but heavy leverage and a rich valuation keep the stock at Hold. Commercial demand is the standout, while margin pressure and debt remain the key risks.
argenx has turned VYVGART into a fast-growing, cash-generating immunology franchise with expanding label breadth and a deepening pipeline. The stock still trades at a premium, but the report argues the commercial momentum supports a Buy.
YPF is shifting from a politically exposed Argentine energy company into a lower-cost shale producer with integrated infrastructure. Strong Vaca Muerta growth, record refining throughput and higher 2026 EBITDA guidance support a Buy rating despite Argentina and commodity risks.
Agilysys posted record fiscal 2026 revenue, with recurring and subscription growth driving the story. The business quality is strong, but the stock’s premium valuation supports only a Hold.
Dominion Energy combines regulated utility stability with strong Virginia data-center demand and a large capital runway. The upside is tempered by heavy leverage, negative free cash flow, and Coastal Virginia Offshore Wind execution risk, supporting a Hold view.
DexCom is executing well with double-digit revenue growth, expanding margins, and broader adoption of G7 15 Day and Stelo. The stock remains a Hold because the business is strong, but valuation already reflects much of the upside.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime